Amylyx Stock Down With Over 82%, After Pivotal ALS Drug FailureAmylyx stock ( NASDAQ:AMLX ) crashed Friday, losing almost all of its value, after the company said its approved ALS treatment, Relyvrio, failed in a pivotal study.
Patients who received Amylyx Pharmaceuticals' ( NASDAQ:AMLX ) Relyvrio showed no significant difference across multiple markers measur